{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:49:38Z","timestamp":1789001378612,"version":"build-2803163510"},"reference-count":153,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Molecules (MDPI, Basel)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>In this review we explore innovative approaches in the treatment of hematologic cancers by combining various therapeutic modalities. We discuss the synergistic potential of combining inhibitors targeting different cellular pathways with immunotherapies, molecular therapies, and hormonal therapies. Examples include combining PI3K inhibitors with proteasome inhibitors, NF-\u03baB inhibitors with immunotherapy checkpoint inhibitors, and neddylation inhibitors with therapies targeting the tumor microenvironment. Additionally, we discuss the potential use of small molecules and peptide inhibitors in hematologic cancer treatment. These multidimensional therapeutic combinations present promising strategies for enhancing treatment efficacy and overcoming resistance mechanisms. However, further clinical research is required to validate their effectiveness and safety profiles in hematologic cancer patients.<\/jats:p>","DOI":"10.3390\/molecules29174280","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T03:16:51Z","timestamp":1725938211000},"page":"4280","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6374-3635","authenticated-orcid":false,"given":"Jan Jakub","family":"Lica","sequence":"first","affiliation":[{"name":"Faculty of Health Science, Powi\u015ble University, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2751-1428","authenticated-orcid":false,"given":"Bhaskar","family":"Pradhan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Faculty of Pharmacy, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1325-7094","authenticated-orcid":false,"given":"Kawthar","family":"Safi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Clinical Chemistry, Faculty of Biology, Medical University of Warsaw, 02-097 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8846-5448","authenticated-orcid":false,"given":"Joanna","family":"Jak\u00f3bkiewicz-Banecka","sequence":"additional","affiliation":[{"name":"Department Medical Biology and Genetics, Faculty of Biology, University of Gda\u0144sk, 80-308 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Transplantology, Faculty of Medicine, Medical University of Gda\u0144sk, 80-214 Gda\u0144sk, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41408-023-00853-3","article-title":"Global Burden of Hematologic Malignancies and Evolution Patterns over the Past 30 Years","volume":"13","author":"Zhang","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/nyas.12362","article-title":"The Bone Marrow Niche, Stem Cells, and Leukemia: Impact of Drugs, Chemicals, and the Environment","volume":"1310","author":"Greim","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Huang, J., Chan, S.C., Ngai, C.H., Lok, V., Zhang, L., Lucero-Prisno, D.E., Xu, W., Zheng, Z.J., Elcarte, E., and Withers, M. (2022). Disease Burden, Risk Factors, and Trends of Leukaemia: A Global Analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.904292"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chu, Y., Liu, Y., Fang, X., Jiang, Y., Ding, M., Ge, X., Yuan, D., Lu, K., Li, P., and Li, Y. (2023). The Epidemiological Patterns of Non-Hodgkin Lymphoma: Global Estimates of Disease Burden, Risk Factors, and Temporal Trends. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1059914"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Sochacka-\u0107wik\u0142a, A., M\u0105czy\u0144ski, M., and Regiec, A. (2022). FDA-Approved Drugs for Hematological Malignancies\u2014The Last Decade Review. Cancers, 14.","DOI":"10.3390\/cancers14010087"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41392-023-01521-5","article-title":"Immunotherapy in Hematologic Malignancies: Achievements, Challenges and Future Prospects","volume":"8","author":"Tang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Yin, Q., Wu, L., Han, L., Zheng, X., Tong, R., Li, L., Bai, L., and Bian, Y. (2023). Immune-Related Adverse Events of Immune Checkpoint Inhibitors: A Review. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1167975"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Shalata, W., Abu-salman, A., Steckbeck, R., Jacob, B.M., Massalha, I., and Yakobson, A. (2021). Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13205218"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/2040620716681749","article-title":"The Role of Combined Fludarabine, Cyclophosphamide and Rituximab Chemoimmunotherapy in Chronic Lymphocytic Leukemia: Current Evidence and Controversies","volume":"8","author":"Skarbnik","year":"2017","journal-title":"Ther. Adv. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Seipel, K., Br\u00fcgger, Y., Mandhair, H., Bacher, U., and Pabst, T. (2022). Rationale for Combining the BCL2 Inhibitor Venetoclax with the PI3K Inhibitor Bimiralisib in the Treatment of IDH2- and FLT3-Mutated Acute Myeloid Leukemia. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232012587"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"6715","DOI":"10.1182\/blood-2022-169764","article-title":"Rituximab, Cyclophosphamide, Etoposide and Prednisone for the Treatment of Post-Transplantation Lymphoproliferative Disorder","volume":"140","author":"Muenzen","year":"2022","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Nogami, A., and Sasaki, K. (2022). Therapeutic Advances in Immunotherapies for Hematological Malignancies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911526"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Allegra, A., Petrarca, C., Di Gioacchino, M., Casciaro, M., Musolino, C., and Gangemi, S. (2022). Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies. Cells, 11.","DOI":"10.3390\/cells11071128"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Han, Y., Liu, Z., Liu, J., Yan, W., Xia, Y., Yue, S., and Yu, J. (2020). Antibody-Based Immunotherapeutic Strategies for the Treatment of Hematological Malignancies. Biomed. Res. Int., 2020.","DOI":"10.1155\/2020\/4956946"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/ITT.S284988","article-title":"Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma","volume":"11","author":"Lin","year":"2022","journal-title":"Immunotargets Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10555-021-09976-0","article-title":"Inhibitors of Immune Checkpoints\u2014PD-1, PD-L1, CTLA-4\u2014New Opportunities for Cancer Patients and a New Challenge for Internists and General Practitioners","volume":"40","author":"Wojtukiewicz","year":"2021","journal-title":"Cancer Metastasis Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","article-title":"LAG-3, TIM-3, and TIGIT: Distinct Functions in Immune Regulation","volume":"57","author":"Joller","year":"2024","journal-title":"Immunity"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41577-019-0224-6","article-title":"TIM3 Comes of Age as an Inhibitory Receptor","volume":"20","author":"Wolf","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1007\/s10637-020-00915-4","article-title":"Phase 1 Study of the Protein Deubiquitinase Inhibitor VLX1570 in Patients with Relapsed and\/or Refractory Multiple Myeloma","volume":"38","author":"Rowinsky","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Peng, Y., Wang, Y., Zhou, C., Mei, W., and Zeng, C. (2022). PI3K\/Akt\/MTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.819128"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Annese, T., Tamma, R., and Ribatti, D. (2022). Update in TIGIT Immune-Checkpoint Role in Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.871085"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Lang, T.J.L., Damm, F., Bullinger, L., and Frick, M. (2023). Mechanisms of Resistance to Small Molecules in Acute Myeloid Leukemia. Cancers, 15.","DOI":"10.3390\/cancers15184573"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Di Costanzo, A., Del Gaudio, N., Conte, L., and Altucci, L. (2020). The Ubiquitin Proteasome System in Hematological Malignancies: New Insight into Its Functional Role and Therapeutic Options. Cancers, 12.","DOI":"10.3390\/cancers12071898"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Wiese, W., Barczuk, J., Racinska, O., Siwecka, N., Rozpedek-Kaminska, W., Slupianek, A., Sierpinski, R., and Majsterek, I. (2023). PI3K\/Akt\/MTOR Signaling Pathway in Blood Malignancies\u2014New Therapeutic Possibilities. Cancers, 15.","DOI":"10.3390\/cancers15215297"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hus, I., Pu\u0142a, B., and Robak, T. (2022). PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives. Cancers, 14.","DOI":"10.3390\/cancers14061571"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/ejh.14065","article-title":"Idelalisib (PI3K\u03b4 Inhibitor) Therapy for Patients with Relapsed\/Refractory Chronic Lymphocytic Leukemia: A Swedish Nation-Wide Real-World Report on Consecutively Identified Patients","volume":"111","author":"Mattsson","year":"2023","journal-title":"Eur. J. Haematol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/hon.3164_367","article-title":"Duvelisib in Patients with Relapsed\/Refractory Peripheral T-Cell Lymphoma from the Phase 2 PRIMO Trial Expansion Phase: Outcomes by Baseline Histology","volume":"41","author":"Jacobsen","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e30398","DOI":"10.1002\/pbc.30398","article-title":"In Vivo Activity of the Dual PI3K\u03b4 and PI3K\u03b3 Inhibitor Duvelisib against Pediatric Acute Lymphoblastic Leukemia Xenografts","volume":"70","author":"Randall","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1080\/14656566.2022.2043273","article-title":"The Evidence to Date on Umbralisib for the Treatment of Refractory Marginal Zone Lymphoma and Follicular Lymphoma","volume":"23","author":"Schweitzer","year":"2022","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s40265-021-01504-2","article-title":"Umbralisib: First Approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.1182\/bloodadvances.2021005132","article-title":"Integrated Safety Analysis of Umbralisib, a Dual PI3K\u03b4\/CK1\u03b5 Inhibitor, in Relapsed\/Refractory Lymphoid Malignancies","volume":"5","author":"Davids","year":"2021","journal-title":"Blood Adv."},{"key":"ref_32","unstructured":"(2024, July 01). Study Details|Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With INHL-(COASTAL)|ClinicalTrials.Gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT04745832."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1038\/s41416-023-02221-1","article-title":"The Emerging Role of PI3K Inhibitors for Solid Tumour Treatment and Beyond","volume":"128","author":"Belli","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"3405","DOI":"10.1007\/s00262-023-03516-1","article-title":"TIM-3 as a Promising Target for Cancer Immunotherapy in a Wide Range of Tumors","volume":"72","author":"Sauer","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41467-021-21099-2","article-title":"Galectin-9 Interacts with PD-1 and TIM-3 to Regulate T Cell Death and Is a Target for Cancer Immunotherapy","volume":"12","author":"Yang","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Cho, H.J., Lee, J., Yoon, S.R., Lee, H.G., and Jung, H. (2020). Regulation of Hematopoietic Stem Cell Fate and Malignancy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134780"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.molcel.2009.04.033","article-title":"The Nfkb1 and Nfkb2 Proteins P105 and P100 Function as the Core of High-Molecular-Weight Heterogeneous Complexes","volume":"34","author":"Savinova","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Anilkumar, S., and Wright-Jin, E. (2024). NF-\u039aB as an Inducible Regulator of Inflammation in the Central Nervous System. Cells, 13.","DOI":"10.20944\/preprints202402.0003.v1"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","article-title":"Targeting NF-\u039aB Pathway for the Therapy of Diseases: Mechanism and Clinical Study","volume":"5","author":"Yu","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1042\/BCJ20210139","article-title":"Inhibitory Feedback Control of NF-\u039aB Signalling in Health and Disease","volume":"478","author":"Prescott","year":"2021","journal-title":"Biochem. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u039aB in Biology and Targeted Therapy: New Insights and Translational Implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.molmed.2016.03.002","article-title":"Noncanonical NF-\u039aB Signaling in Health and Disease","volume":"22","author":"Cildir","year":"2016","journal-title":"Trends Mol. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3390\/kinasesphosphatases2010002","article-title":"The Yin and Yang of I\u03baB Kinases in Cancer","volume":"2","author":"Salvi","year":"2023","journal-title":"Kinases Phosphatases"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ghosh, G., and Wang, V.Y.F. (2021). Origin of the Functional Distinctiveness of NF-\u039aB\/P52. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.764164"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ramadass, V., Vaiyapuri, T., and Tergaonkar, V. (2020). Small Molecule NF-\u039aB Pathway Inhibitors in Clinic. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21145164"},{"key":"ref_46","unstructured":"(2024, July 01). BAY11-7082 Inhibits the Expression of Tissue Factor and Plasminogen Activator Inhibitor-1 in Type-II Alveolar Epithelial Cells Following TNF-\u03b1 Stimulation via the NF-\u03baB Pathway. Available online: https:\/\/www.spandidos-publications.com\/10.3892\/etm.2020.9608."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Meng, T., Xiao, D., Muhammed, A., Deng, J., Chen, L., and He, J. (2021). Anti-Inflammatory Action and Mechanisms of Resveratrol. Molecules, 26.","DOI":"10.3390\/molecules26010229"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Xiao, A., Akilov, O.E., Xiao, A., and Akilov, O.E. (2022). Targeting the CD47-SIRP\u03b1 Axis: Present Therapies and the Future for Cutaneous T-Cell Lymphoma. Cells, 11.","DOI":"10.3390\/cells11223591"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"100070","DOI":"10.1016\/j.iotech.2022.100070","article-title":"CD47\u2013SIRP\u03b1-Targeted Therapeutics: Status and Prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e20507","DOI":"10.1016\/j.heliyon.2023.e20507","article-title":"Don\u2019t Eat Me\/Eat Me Signals as a Novel Strategy in Cancer Immunotherapy","volume":"9","author":"Khalaji","year":"2023","journal-title":"Heliyon"},{"key":"ref_51","first-page":"100268","article-title":"CD47-Targeting Antibodies as a Novel Therapeutic Strategy in Hematologic Malignancies","volume":"16","author":"Sun","year":"2021","journal-title":"Leuk. Res. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.apsb.2022.12.016","article-title":"Building on the Backbone of CD47-Based Therapy in Cancer: Combination Strategies, Mechanisms, and Future Perspectives","volume":"13","author":"Ye","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2174\/1871520615666150305111257","article-title":"Neddylation Pathway as a Novel Anti-Cancer Target: Mechanistic Investigation and Therapeutic Implication","volume":"15","author":"Jiang","year":"2015","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Chen, Y., and Sun, L. (2022). Inhibition of NEDD8 NEDDylation Induced Apoptosis in Acute Myeloid Leukemia Cells via P53 Signaling Pathway. Biosci. Rep., 42.","DOI":"10.1042\/BSR20220994"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s12943-019-0979-1","article-title":"Neddylation: A Novel Modulator of the Tumor Microenvironment","volume":"18","author":"Zhou","year":"2019","journal-title":"Mol. Cancer"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Liu, D., Che, X., and Wu, G. (2024). Deciphering the Role of Neddylation in Tumor Microenvironment Modulation: Common Outcome of Multiple Signaling Pathways. Biomark. Res., 12.","DOI":"10.1186\/s40364-023-00545-x"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41388-020-01586-4","article-title":"TAS4464, a NEDD8-Activating Enzyme Inhibitor, Activates Both Intrinsic and Extrinsic Apoptotic Pathways via c-Myc-Mediated Regulation in Acute Myeloid Leukemia","volume":"40","author":"Ochiiwa","year":"2021","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.apsb.2019.09.005","article-title":"Anticancer Drug Discovery by Targeting Cullin Neddylation","volume":"10","author":"Yu","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41392-024-01800-9","article-title":"Protein Neddylation and Its Role in Health and Diseases","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100811","DOI":"10.1016\/j.tranon.2020.100811","article-title":"Programmed Cell Death-Ligand 2: A Neglected But Important Target in the Immune Response to Cancer?","volume":"13","author":"Solinas","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Shiravand, Y., Khodadadi, F., Kashani, S.M.A., Hosseini-Fard, S.R., Hosseini, S., Sadeghirad, H., Ladwa, R., O\u2019byrne, K., and Kulasinghe, A. (2022). Immune Checkpoint Inhibitors in Cancer Therapy. Curr. Oncol., 29.","DOI":"10.3390\/curroncol29050247"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination Strategies with PD-1\/PD-L1 Blockade: Current Advances and Future Directions","volume":"21","author":"Yi","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40425-015-0067-z","article-title":"Combination Immunotherapy with \u03b1-CTLA-4 and \u03b1-PD-L1 Antibody Blockade Prevents Immune Escape and Leads to Complete Control of Metastatic Osteosarcoma","volume":"3","author":"Lussier","year":"2015","journal-title":"J. Immunother. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Eng. J. Med."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab Monotherapy in Patients with Treatment-Refractory Multiple Myeloma (SIRIUS): An Open-Label, Randomised, Phase 2 Trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N. Eng. J. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N. Eng. J. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Eng. J. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3747\/co.2007.118","article-title":"Alemtuzumab in Chronic Lymphocytic Leukemia","volume":"14","author":"Fraser","year":"2007","journal-title":"Curr. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41419-023-06391-x","article-title":"Anti-CTLA-4 Nanobody as a Promising Approach in Cancer Immunotherapy","volume":"15","author":"Babamohamadi","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Sobhani, N., Tardiel-Cyril, D.R., Davtyan, A., Generali, D., Roudi, R., and Li, Y. (2021). CTLA-4 in Regulatory T Cells for Cancer Immunotherapy. Cancers, 13.","DOI":"10.20944\/preprints202102.0150.v1"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Rossi, F., Fredericks, N., Snowden, A., Allegrezza, M.J., and Moreno-Nieves, U.Y. (2022). Next Generation Natural Killer Cells for Cancer Immunotherapy. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.886429"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Jogalekar, M.P., Rajendran, R.L., Khan, F., Dmello, C., Gangadaran, P., and Ahn, B.C. (2022). CAR T-Cell-Based Gene Therapy for Cancers: New Perspectives, Challenges, and Clinical Developments. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.925985"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1210\/endrev\/bnab004","article-title":"Macrophage Responses to Environmental Stimuli During Homeostasis and Disease","volume":"42","author":"Rasheed","year":"2021","journal-title":"Endocr. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.apsb.2020.04.004","article-title":"The Role of Tumor-Associated Macrophages (TAMs) in Tumor Progression and Relevant Advance in Targeted Therapy","volume":"10","author":"Yang","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Xie, Y., Yang, H., Yang, C., He, L., Zhang, X., Peng, L., Zhu, H., and Gao, L. (2022). Role and Mechanisms of Tumor-Associated Macrophages in Hematological Malignancies. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.933666"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","article-title":"The Paradoxical Role of Cytokines and Chemokines at the Tumor Microenvironment: A Comprehensive Review","volume":"29","author":"Ghosh","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/BS9.0000000000000014","article-title":"Macrophages in Leukemia Microenvironment","volume":"1","author":"Wang","year":"2019","journal-title":"Blood Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/s41392-023-01522-4","article-title":"Immune Checkpoint Therapy for Solid Tumours: Clinical Dilemmas and Future Trends","volume":"8","author":"Sun","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as Tools and Targets in Cancer Therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nature Reviews Drug Discov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1017\/S1462399411001943","article-title":"Inflammation and Wound Healing: The Role of the Macrophage","volume":"13","author":"Koh","year":"2011","journal-title":"Expert Rev. Mol. Med."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Yang, S., Zhao, M., and Jia, S. (2023). Macrophage: Key Player in the Pathogenesis of Autoimmune Diseases. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1080310"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR Race to Cancer Immunotherapy: From CAR T, CAR NK to CAR Macrophage Therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"465","DOI":"10.17305\/bb.2023.9675","article-title":"CAR-Macrophage versus CAR-T for Solid Tumors: The Race between a Rising Star and a Superstar","volume":"24","author":"Chen","year":"2024","journal-title":"Biomol. Biomed."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 Identifies a CD8+ T-Cell Exhaustion Phenotype in Mice with Disseminated Acute Myelogenous Leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1158\/0008-5472.CAN-13-2908","article-title":"PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen-Specific CD8+ T Cells Induced by Melanoma Vaccines","volume":"74","author":"Fourcade","year":"2014","journal-title":"Cancer Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s12185-013-1433-6","article-title":"TIM-3 as a Novel Therapeutic Target for Eradicating Acute Myelogenous Leukemia Stem Cells","volume":"98","author":"Kikushige","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Kok, V.C. (2020). Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1\/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00268"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Tian, T., and Li, Z. (2021). Targeting Tim-3 in Cancer with Resistance to PD-1\/PD-L1 Blockade. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.731175"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/s41419-023-05961-3","article-title":"TIGIT, a Novel Immune Checkpoint Therapy for Melanoma","volume":"14","author":"Tang","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Zhang, P., Liu, X., Gu, Z., Jiang, Z., Zhao, S., Song, Y., and Yu, J. (2024). Targeting TIGIT for Cancer Immunotherapy: Recent Advances and Future Directions. Biomark. Res., 12.","DOI":"10.1186\/s40364-023-00543-z"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.drudis.2020.10.028","article-title":"The Emerging Nature of Ubiquitin-Specific Protease 7 (USP7): A New Target in Cancer Therapy","volume":"26","author":"Nininahazwe","year":"2021","journal-title":"Drug Discov. Today"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00204-023-03440-4","article-title":"Development and Safety of PI3K Inhibitors in Cancer","volume":"97","author":"Yu","year":"2023","journal-title":"Arch. Toxicol."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Zhu, S., Sun, P., Bennett, S., Charlesworth, O., Tan, R., Peng, X., Gu, Q., Kujan, O., and Xu, J. (2023). The Therapeutic Effect and Mechanism of Parthenolide in Skeletal Disease, Cancers, and Cytokine Storm. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1111218"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"49","DOI":"10.32604\/or.2023.042383","article-title":"Opportunities and Challenges of CD47-Targeted Therapy in Cancer Immunotherapy","volume":"32","author":"Chen","year":"2024","journal-title":"Oncol. Res."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Gai, W., Peng, Z., Liu, C.H., Zhang, L., and Jiang, H. (2021). Advances in Cancer Treatment by Targeting the Neddylation Pathway. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.653882"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/JBM.S233059","article-title":"Good Profile of Efficacy\/Tolerance of Bortezomib or Idelalisib in Waldenstr\u00f6m Macroglobulinemia Associated with Acquired Von Willebrand Syndrome","volume":"11","author":"Rimelen","year":"2020","journal-title":"J. Blood Med."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/s43018-021-00218-4","article-title":"The Present and Future of PI3K Inhibitors for Cancer Therapy","volume":"2","author":"Castel","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e1261779","DOI":"10.1080\/2162402X.2016.1261779","article-title":"Adaptive Resistance to Anti-PD1 Therapy by Tim-3 Upregulation Is Mediated by the PI3K-Akt Pathway in Head and Neck Cancer","volume":"6","author":"Shayan","year":"2017","journal-title":"Oncoimmunology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11864-023-01049-4","article-title":"Small-Molecule Compounds Boost CAR-T Cell Therapy in Hematological Malignancies","volume":"24","author":"Cao","year":"2023","journal-title":"Cur.r Treat Options Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Varayathu, H., Sarathy, V., Thomas, B.E., Mufti, S.S., and Naik, R. (2021). Combination Strategies to Augment Immune Check Point Inhibitors Efficacy-Implications for Translational Research. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.559161"},{"key":"ref_102","first-page":"E966","article-title":"Therapeutic Antitumor Immunity by Checkpoint Blockade Is Enhanced by Ibrutinib, an Inhibitor of Both BTK and ITK","volume":"112","author":"Kohrt","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"968","DOI":"10.3324\/haematol.2019.238154","article-title":"Combining Ibrutinib and Checkpoint Blockade Improves CD8+ T-Cell Function and Control of Chronic Lymphocytic Leukemia in Em-TCL1 Mice","volume":"106","author":"Hanna","year":"2021","journal-title":"Haematologica"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2077898","DOI":"10.1080\/2162402X.2022.2077898","article-title":"Trial Watch: Combination of Tyrosine Kinase Inhibitors (TKIs) and Immunotherapy","volume":"11","author":"Petrazzuolo","year":"2022","journal-title":"Oncoimmunology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s00018-023-05098-8","article-title":"Targeting the NF-\u039aB Pathway as a Potential Regulator of Immune Checkpoints in Cancer Immunotherapy","volume":"81","author":"Ebrahimi","year":"2024","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"3264","DOI":"10.1136\/jitc-2021-003264","article-title":"The Tumor-Targeted CD40 Agonist CEA-CD40 Promotes T Cell Priming via a Dual Mode of Action by Increasing Antigen Delivery to Dendritic Cells and Enhancing Their Activation","volume":"10","author":"Sum","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Li, L., Li, Y., Liu, G., Hoffman, R.M., and Jia, L. (2021). Neddylation Regulates Macrophages and Implications for Cancer Therapy. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.681186"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12964-023-01433-5","article-title":"Interplay between Proteasome Inhibitors and NF-\u039aB Pathway in Leukemia and Lymphoma: A Comprehensive Review on Challenges Ahead of Proteasome Inhibitors","volume":"22","author":"Pakjoo","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Logghe, T., van Zwol, E., Immordino, B., Van den Cruys, K., Peeters, M., Giovannetti, E., and Bogers, J. (2024). Hyperthermia in Combination with Emerging Targeted and Immunotherapies as a New Approach in Cancer Treatment. Cancers, 16.","DOI":"10.3390\/cancers16030505"},{"key":"ref_110","first-page":"953","article-title":"Neddylation Inhibitor, MLN4924 Suppresses Angiogenesis in Huvecs and Solid Cancers: In Vitro and in Vivo Study","volume":"10","author":"Shi","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e167894","DOI":"10.1172\/JCI167894","article-title":"Waking Immune-Resistant Tumors with Neddylation","volume":"133","author":"Huntoon","year":"2023","journal-title":"J. Clin. Investig."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13045-023-01485-7","article-title":"Targeting NEDD8-Activating Enzyme for Cancer Therapy: Developments, Clinical Trials, Challenges and Future Research Directions","volume":"16","author":"Fu","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3762","DOI":"10.1038\/s41467-023-39374-9","article-title":"Targeting Neddylation Sensitizes Colorectal Cancer to Topoisomerase I Inhibitors by Inactivating the DCAF13-CRL4 Ubiquitin Ligase Complex","volume":"14","author":"Sun","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1186\/s12935-022-02778-6","article-title":"CAR-T Cell Combination Therapy: The next Revolution in Cancer Treatment","volume":"22","author":"Tondok","year":"2022","journal-title":"Cancer Cell Int."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Moreno, M.A., Ciudad-Guti\u00e9rrez, P., Jaramillo-Ruiz, D., Reguera-Ortega, J.L., Abdel-kader Mart\u00edn, L., and Flores-Moreno, S. (2023). Combined or Sequential Treatment with Immune Checkpoint Inhibitors and Car-T Cell Therapies for the Management of Haematological Malignancies: A Systematic Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241914780"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1158\/1078-0432.CCR-21-4332","article-title":"Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment","volume":"28","author":"Kleinendorst","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Lu, Q., Li, H., Wu, Z., Zhu, Z., Zhang, Z., Yang, D., and Tong, A. (2024). BCMA\/CD47-Directed Universal CAR-T Cells Exhibit Excellent Antitumor Activity in Multiple Myeloma. J. Nanobiotechnology, 22.","DOI":"10.1186\/s12951-024-02512-6"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e004589","DOI":"10.1136\/jitc-2022-004589","article-title":"CD47\/SIRP\u03b1 Axis: Bridging Innate and Adaptive Immunity","volume":"10","author":"Scheeren","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Ahire, V., Ahmadi Bidakhvidi, N., Boterberg, T., Chaudhary, P., Chevalier, F., Daems, N., Delbart, W., Baatout, S., Deroose, C.M., and Fernandez-Palomo, C. (2023). Radiobiology of Combining Radiotherapy with Other Cancer Treatment Modalities. Radiobiology Textbook, Springer.","DOI":"10.1007\/978-3-031-18810-7_6"},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"Vaz De Freitas, M., Fr\u00e2ncio, L., Haleva, L., and Da Silveira Matte, U. (2022). Protection Is Not Always a Good Thing: The Immune System\u2019s Impact on Gene Therapy. Genet. Mol. Biol., 45.","DOI":"10.1590\/1678-4685-gmb-2022-0046"},{"key":"ref_121","first-page":"161","article-title":"Hyperthermia: Role and Risk Factor for Cancer Treatment","volume":"10","author":"Jha","year":"2016","journal-title":"Achiev. Life Sci."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Agarwal, N., Rotz, S., and Hanna, R. (2023). Medical Emergencies in Pediatric Blood & Marrow Transplant and Cellular Therapies. Front. Pediatr., 11.","DOI":"10.3389\/fped.2023.1075644"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1182\/hematology.2020000089","article-title":"Management of Toxicities Associated with Targeted Therapies for Acute Myeloid Leukemia: When to Push through and When to Stop","volume":"2020","author":"Wang","year":"2020","journal-title":"Hematology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"12838","DOI":"10.1021\/acs.jmedchem.2c00673","article-title":"Histone Deacetylase and Enhancer of Zeste Homologue 2 Dual Inhibitors Presenting a Synergistic Effect for the Treatment of Hematological Malignancies","volume":"65","author":"Lu","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_125","doi-asserted-by":"crossref","unstructured":"Xu, J., Dong, X., Huang, D.C.S., Xu, P., Zhao, Q., and Chen, B. (2023). Current Advances and Future Strategies for BCL-2 Inhibitors: Potent Weapons against Cancers. Cancers, 15.","DOI":"10.3390\/cancers15204957"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.exphem.2017.07.003","article-title":"Targeted Therapies in Hematological Malignancies Using Therapeutic Monoclonal Antibodies against Eph Family Receptors","volume":"54","author":"Charmsaz","year":"2017","journal-title":"Exp. Hematol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2040620719866081","DOI":"10.1177\/2040620719866081","article-title":"Insights into Novel Emerging Epigenetic Drugs in Myeloid Malignancies","volume":"10","author":"Chandhok","year":"2019","journal-title":"Ther. Adv. Hematol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ajh.25463","article-title":"Single Agents vs Combination Chemotherapy in Relapsed and Refractory Peripheral T-Cell Lymphoma: Results from the Comprehensive Oncology Measures for Peripheral T-Cell Lymphoma Treatment (COMPLETE) Registry","volume":"94","author":"Stuver","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Uson Junior, P.L.S., Santos, V.M., Bugano, D.D.G., Victor, E.D.S., Rother, E.T., and Maluf, F.C. (2019). Systematic Review and Meta-Analysis of Docetaxel Perioperative Chemotherapy Regimens in Gastric and Esophagogastric Tumors. Sci. Rep., 9.","DOI":"10.1038\/s41598-019-52334-y"},{"key":"ref_130","first-page":"CD004064","article-title":"Chemotherapy for Advanced Gastric Cancer","volume":"8","author":"Wagner","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Gresham, G.K., Wells, G.A., Gill, S., Cameron, C., and Jonker, D.J. (2014). Chemotherapy Regimens for Advanced Pancreatic Cancer: A Systematic Review and Network Meta-Analysis. BMC Cancer, 14.","DOI":"10.1186\/1471-2407-14-471"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1287\/mnsc.2015.2363","article-title":"An Analytics Approach to Designing Combination Chemotherapy Regimens for Cancer","volume":"62","author":"Bertsimas","year":"2016","journal-title":"Manag. Sci."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/asheducation-2015.1.286","article-title":"Novel Combination Approaches for Myeloma","volume":"2015","author":"Lonial","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1200\/JCO.21.02810","article-title":"The Time Toxicity of Cancer Treatment","volume":"40","author":"Gupta","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"6633","DOI":"10.1158\/1078-0432.CCR-18-3882","article-title":"Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity\/Preclinical Exposure-Efficacy Modeling","volume":"25","author":"Bottino","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Sergunova, V., Leesment, S., Kozlov, A., Inozemtsev, V., Platitsina, P., Lyapunova, S., Onufrievich, A., Polyakov, V., and Sherstyukova, E. (2022). Investigation of Red Blood Cells by Atomic Force Microscopy. Sensors, 22.","DOI":"10.3390\/s22052055"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Magazz\u00f9, A., and Marcuello, C. (2023). Investigation of Soft Matter Nanomechanics by Atomic Force Microscopy and Optical Tweezers: A Comprehensive Review. Nanomaterials, 13.","DOI":"10.3390\/nano13060963"},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Uscanga-Palomeque, A.C., Ch\u00e1vez-Escamilla, A.K., Alvizo-B\u00e1ez, C.A., Saavedra-Alonso, S., Terrazas-Armend\u00e1riz, L.D., Tamez-Guerra, R.S., Rodr\u00edguez-Padilla, C., and Alcocer-Gonz\u00e1lez, J.M. (2023). CAR-T Cell Therapy: From the Shop to Cancer Therapy. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242115688"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12668-016-0191-3","article-title":"Discrimination Between Normal and Cancerous Cells Using AFM","volume":"6","author":"Lekka","year":"2016","journal-title":"Bionanoscience"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jval.2022.04.1738","article-title":"Developing Patient-Centered Real-World Evidence: Emerging Methods Recommendations from a Consensus Process","volume":"26","author":"Oehrlein","year":"2023","journal-title":"Value Health"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s40290-022-00458-4","article-title":"Using Patient Perspectives to Inform Better Clinical Trial Design and Conduct: Current Trends and Future Directions","volume":"37","author":"Faulkner","year":"2023","journal-title":"Pharm. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","article-title":"Development of Immunotherapy Combination Strategies in Cancer","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining Immunotherapy and Targeted Therapies in Cancer Treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1200\/JCO.2024.42.16_suppl.6550","article-title":"Predictive Biomarkers of Response to the IRAK4\/FLT3 Inhibitor Emavusertib in Hematological Malignancies","volume":"42","author":"Metzeler","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/imr.12391","article-title":"Immunocytokines and Bispecific Antibodies: Two Complementary Strategies for the Selective Activation of Immune Cells at the Tumor Site","volume":"270","author":"Kiefer","year":"2016","journal-title":"Immunol. Rev."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Mun, J.Y., Leem, S.H., Lee, J.H., and Kim, H.S. (2022). Dual Relationship Between Stromal Cells and Immune Cells in the Tumor Microenvironment. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.864739"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1002\/mco2.203","article-title":"Hypoxia Signaling in Cancer: Implications for Therapeutic Interventions","volume":"4","author":"Zhuang","year":"2023","journal-title":"MedComm"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"2040620718816698","DOI":"10.1177\/2040620718816698","article-title":"Epigenetic Therapy Combinations in Acute Myeloid Leukemia: What Are the Options?","volume":"10","author":"Bewersdorf","year":"2019","journal-title":"Ther. Adv Hematol"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"9","DOI":"10.5387\/fms.2018-02","article-title":"Targeted Therapy According to next Generation Sequencing-Based Panel Sequencing","volume":"64","author":"Saito","year":"2018","journal-title":"Fukushima J. Med. Sci."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-020-00956-5","article-title":"Advances in Synthetic Lethality for Cancer Therapy: Cellular Mechanism and Clinical Translation","volume":"13","author":"Topatana","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"e36490","DOI":"10.2196\/36490","article-title":"A Review of Artificial Intelligence Applications in Hematology Management: Current Practices and Future Prospects","volume":"24","author":"Elomri","year":"2022","journal-title":"J. Med. Internet Res."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Lin, W., and Zhu, L. (2022). Targeted Drug Delivery for the Treatment of Blood Cancers. Molecules, 27.","DOI":"10.3390\/molecules27041310"},{"key":"ref_153","first-page":"164","article-title":"Strategies to Mitigate the On- and off-Target Toxicities of Recombinant Immunotoxins: An Antibody Engineering Perspective","volume":"5","author":"Li","year":"2022","journal-title":"Antib. Ther."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/17\/4280\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:52:30Z","timestamp":1760111550000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/29\/17\/4280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,9]]},"references-count":153,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["molecules29174280"],"URL":"https:\/\/doi.org\/10.3390\/molecules29174280","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,9]]}}}